MVCD2
MCID: MCR112
MIFTS: 41

Microvascular Complications of Diabetes 2 (MVCD2)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 2

MalaCards integrated aliases for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 56 73 29 13 6 39
Proliferative Diabetic Retinopathy 73 71
Diabetic Nephropathy 73 71
Mvcd2 56 73
Microvascular Complications of Diabetes, Susceptibility to, 2 56
Proliferative Retinopathy, Diabetic, Susceptibility to 56
End-Stage Renal Disease, Diabetic, Susceptibility to 56
Proliferative Retinopathy, Diabetic 56
End-Stage Renal Disease, Diabetic 56
Diabetic End-Stage Renal Disease 73

Classifications:



External Ids:

OMIM 56 612623
OMIM Phenotypic Series 56 PS603933
MeSH 43 D048909
UMLS 71 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 2: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 2, also known as proliferative diabetic retinopathy, is related to microvascular complications of diabetes 3 and microvascular complications of diabetes 5. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Methylcobalamin and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and kidney.

More information from OMIM: 612623 PS603933

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 496)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 12.3
2 microvascular complications of diabetes 5 12.1
3 background diabetic retinopathy 12.1
4 vitreoretinopathy, neovascular inflammatory 11.9
5 severe nonproliferative diabetic retinopathy 11.9
6 microvascular complications of diabetes 7 11.8
7 microvascular complications of diabetes 1 11.7
8 retinal detachment 11.1
9 macular retinal edema 10.9
10 renal fibrosis 10.9
11 macular holes 10.9
12 neovascular glaucoma 10.8
13 yemenite deaf-blind hypopigmentation syndrome 10.8
14 diabetic macular edema 10.8
15 vitreoretinopathy 10.7
16 glomerulonephritis 10.7
17 nephrotic syndrome 10.6
18 rubeosis iridis 10.6
19 end stage renal disease 10.6
20 retinal ischemia 10.6
21 eye disease 10.6
22 intraocular pressure quantitative trait locus 10.5
23 retinal disease 10.5
24 uremia 10.5
25 hypertension, essential 10.5
26 iga glomerulonephritis 10.5
27 hyperglycemia 10.5
28 vitreous detachment 10.5
29 membranous nephropathy 10.4
30 endophthalmitis 10.4
31 uveitis 10.4
32 glomerular disease 10.4
33 neuroretinitis 10.4
34 retinal vascular disease 10.4
35 retinitis 10.4
36 diabetes mellitus 10.4
37 kidney hypertrophy 10.4
38 preretinal fibrosis 10.4
39 hyperinsulinism 10.4
40 nephrosclerosis 10.4
41 hyperuricemia 10.3
42 diabetes mellitus, type i 10.3
43 atherosclerosis susceptibility 10.3
44 diabetes mellitus, noninsulin-dependent 10.3
45 retinitis pigmentosa 10.3
46 insulin-like growth factor i 10.3
47 retinoschisis 1, x-linked, juvenile 10.3
48 48,xyyy 10.3
49 rapidly involuting congenital hemangioma 10.3
50 proteasome-associated autoinflammatory syndrome 1 10.3

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:



Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM:

612623

Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 402)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
6
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
7
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
8
Methyldopa Approved Phase 4 555-30-6 38853
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Bevacizumab Approved, Investigational Phase 4 216974-75-3
12
Dipivefrin Approved Phase 4 52365-63-6 3105
13
Ranibizumab Approved Phase 4 347396-82-1 459903
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Povidone-iodine Approved Phase 4 25655-41-8
18
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
19
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
20
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
21
Probucol Approved, Investigational Phase 4 23288-49-5 4912
22
Ramipril Approved Phase 4 87333-19-5 5362129
23
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
24
Doxazosin Approved Phase 4 74191-85-8 3157
25
Atorvastatin Approved Phase 4 134523-00-5 60823
26
Indapamide Approved Phase 4 26807-65-8 3702
27
Nisoldipine Approved Phase 4 63675-72-9 4499
28
Trandolapril Approved Phase 4 87679-37-6 5484727
29
Amlodipine Approved Phase 4 88150-42-9 2162
30
Verapamil Approved Phase 4 52-53-9 2520
31
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
32
Insulin glulisine Approved Phase 4 207748-29-6
33
Insulin glargine Approved Phase 4 160337-95-1
34
Liraglutide Approved Phase 4 204656-20-2 44147092
35
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
36
Nitric Oxide Approved Phase 4 10102-43-9 145068
37
Allopurinol Approved Phase 4 315-30-0 2094
38
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
39
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
40
Insulin lispro Approved Phase 4 133107-64-9
41
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
42
Clonidine Approved Phase 4 4205-90-7 2803
43
Atenolol Approved Phase 4 29122-68-7 2249
44
Glimepiride Approved Phase 4 93479-97-1 3476
45
Hydralazine Approved Phase 4 86-54-4 3637
46
Terazosin Approved Phase 4 63590-64-7 5401
47
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
48
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
49
Febuxostat Approved Phase 4 144060-53-7 134018
50
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510

Interventional clinical trials:

(show top 50) (show all 623)
# Name Status NCT ID Phase Drugs
1 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
2 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
3 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
4 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
5 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
6 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
7 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
8 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
9 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
10 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
11 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
12 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
13 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
14 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
15 A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
16 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
17 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
18 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
19 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
20 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
21 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
22 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
23 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
24 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
25 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
26 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
27 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
28 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
29 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
30 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
31 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
32 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
33 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
34 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
35 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
36 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
37 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
38 Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness Completed NCT01504724 Phase 4 bevacizumab
39 Ranibizumab and Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema Completed NCT04089605 Phase 4 dexamethasone implant;Ranibizumab
40 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
41 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
42 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
43 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
44 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
45 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
46 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
47 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
48 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
49 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
50 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH

Search NIH Clinical Center for Microvascular Complications of Diabetes 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 2

Genetic tests related to Microvascular Complications of Diabetes 2:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 2 29 EPO

Anatomical Context for Microvascular Complications of Diabetes 2

MalaCards organs/tissues related to Microvascular Complications of Diabetes 2:

40
Endothelial, Eye, Kidney, Retina, Pancreas, Monocytes, Heart

Publications for Microvascular Complications of Diabetes 2

Articles related to Microvascular Complications of Diabetes 2:

(show top 50) (show all 4045)
# Title Authors PMID Year
1
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. 6 56 61
18458324 2008
2
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. 61 56
16120858 2005
3
Increased Expression of Growth Hormone-Releasing Hormone in Fibrinous Inflammation of Proliferative Diabetic Retinopathy. 61
32061756 2020
4
Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice. 61
32209344 2020
5
Serum myostatin levels are positively associated with diabetic retinopathy in individuals with type 2 diabetes mellitus. 61
32354624 2020
6
Different Scan Protocols Affect the Detection Rates of Diabetic Retinopathy Lesions by Wide-Field Swept-Source Optical Coherence Tomography Angiography. 61
32205122 2020
7
Intravitreal Conbercept Injection as an Adjuvant in Vitrectomy with Silicone Oil Infusion for Severe Proliferative Diabetic Retinopathy. 61
32186940 2020
8
Periostin and tenascin-C interaction promotes angiogenesis in ischemic proliferative retinopathy. 61
32518264 2020
9
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. 61
31567817 2020
10
Prognostic factors of revitrectomy for complications in eyes with proliferative diabetic retinopathy: a retrospective multicentre study. 61
31674137 2020
11
What Is the Impact of Intraoperative Microscope-Integrated OCT in Ophthalmic Surgery? Relevant Applications and Outcomes. A Systematic Review. 61
32498222 2020
12
Proliferative diabetic retinopathy as onset of type 1 diabetes. 61
31866090 2020
13
Lutein and zeaxanthin attenuates VEGF-induced neovascularisation in human retinal microvascular endothelial cells through a Nox4-dependent pathway. 61
32522479 2020
14
Disproportion of lamellar capillary non-perfusion in proliferative diabetic retinopathy on optical coherence tomography angiography. 61
31519548 2020
15
Statin reduces the incidence of diabetic retinopathy and its need for intervention: A systematic review and meta-analysis. 61
32530705 2020
16
Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy. 61
32356244 2020
17
Intraocular tumour necrosis factor ligand related molecule 1 A links disease progression of proliferative diabetic retinopathy after primary vitrectomy. 61
32064668 2020
18
Ocular decompression retinopathy following intracameral bevacizumab injection in a case of proliferative diabetic retinopathy with neovascular glaucoma. 61
32461484 2020
19
Spontaneous closure of secondary eccentric macular holes following vitreoretinal surgery. 61
32541438 2020
20
Relationship between corneal sensitivity and diabetic retinopathy among diabetics attending a Nigerian Teaching Hospital. 61
32506293 2020
21
Vitreoretinal Interface Slab in OCT Angiography for Detecting Diabetic Retinal Neovascularization. 61
32107187 2020
22
Screening for diabetic retinopathy in diabetic patients with a mydriasis-free, full-field flicker electroretinogram recording device. 61
31720980 2020
23
Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c. 61
32494901 2020
24
Comparison of inflammatory cytokines levels in the aqueous humor with diabetic retinopathy. 61
32556740 2020
25
Vascular resistance of carotid and vertebral arteries is associated with retinal microcirculation measured by laser speckle flowgraphy in patients with type 2 diabetes mellitus. 61
32502691 2020
26
VASCULAR COMPLEXITY ANALYSIS IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF DIABETIC RETINOPATHY. 61
32568980 2020
27
Longitudinal Angiographic Evidence that Intraretinal Microvascular Abnormalities Can Evolve into Neovascularization. 61
32544625 2020
28
Association Between Alterations of the Choriocapillaris Microcirculation and Visual Function and Cone Photoreceptors in Patients With Diabetes. 61
32492109 2020
29
Quantification of diabetic macular ischemia using novel three-dimensional optical coherence tomography angiography metrics. 61
32526048 2020
30
Correlation between markers of renal function and sight-threatening diabetic retinopathy in type 2 diabetes: a longitudinal study in an Indian clinic population. 61
32475840 2020
31
Incidence and risk factors for intraocular pressure rise after transconjunctival vitrectomy. 61
32317451 2020
32
VEGF-Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy. 61
31550048 2020
33
Stabilization of myeloid-derived HIFs promotes vascular regeneration in retinal ischemia. 61
31583505 2020
34
Ocular Manifestations in Hemodialysis Patients and Short-Term Changes in Ophthalmologic Findings. 61
32400088 2020
35
Wide-field optical coherence tomography angiography for the detection of proliferative diabetic retinopathy. 61
32474692 2020
36
Analysis of risk factors for progressive fibrovascular proliferation in proliferative diabetic retinopathy. 61
32468429 2020
37
Interleukin-11 Overexpression and M2 Macrophage Density are Associated with Angiogenic Activity in Proliferative Diabetic Retinopathy. 61
31403827 2020
38
Changes of visual fields in treatment of proliferative diabetic retinopathy: a systematic review. 61
32421255 2020
39
Retinal Nonperfusion in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation Assessed by Widefield OCT Angiography. 61
32006481 2020
40
Vitreous hemorrhage in diabetes patients with proliferative diabetic retinopathy undergoing hemodialysis. 61
31618517 2020
41
Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy. 61
31586167 2020
42
Efficacy of conbercept combined with panretinal photocoagulation in the treatment of proliferative diabetic retinopathy. 61
32472048 2020
43
Relationships among Retinal Nonperfusion, Neovascularization, and Vascular Endothelial Growth Factor Levels in Quiescent Proliferative Diabetic Retinopathy. 61
32414164 2020
44
PATIENTS PRESENTING EMERGENTLY WITH PROLIFERATIVE DIABETIC RETINOPATHY: Follow-up and Factors Associated With Compliance. 61
30897069 2020
45
Vascular changes precede tomographic changes in diabetic eyes without retinopathy and improve artificial intelligence diagnostics. 61
32392370 2020
46
"Delamination Plus": A Technique to Reduce Immediate Postoperative Diabetic Cavity Hemorrhage. 61
32412945 2020
47
Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta-analysis. 61
32167242 2020
48
Early-onset type 2 diabetes: A high-risk factor for proliferative diabetic retinopathy (PDR) in patients with microalbuminuria. 61
32384512 2020
49
Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study. 61
32472172 2020
50
[Supplementary statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on treatment of proliferative diabetic retinopathy : Status November 2019]. 61
32430606 2020

Variations for Microvascular Complications of Diabetes 2

ClinVar genetic disease variations for Microvascular Complications of Diabetes 2:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EPO NM_000799.3(EPO):c.-1306C>ASNV risk factor 16602 rs1617640 7:100317298-100317298 7:100719675-100719675

Expression for Microvascular Complications of Diabetes 2

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 2.

Pathways for Microvascular Complications of Diabetes 2

GO Terms for Microvascular Complications of Diabetes 2

Sources for Microvascular Complications of Diabetes 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....